Key opinion leaders provide some advice for the public regarding COVID-19 booster shots and look to the future of the pandemic.
The key is using the right dose on the right patient at the right time.
The evolution of treatment for hepatitis C virus during the past 15 years has been astounding, and we now are able to talk about how HCV could be eliminated.
Nabin K. Shrestha, MD, MPH, evaluates the Cleveland Clinic's Outpatient Parenteral Antimicrobial Therapy (OPAT) program, revealing its effectiveness in managing infections while highlighting challenges in monitoring and the impact of infectious disease pharmacists on patient outcomes.
Although fecal microbiota, live-jslm (Rebyota; RBX2660) is the first fecal microbiota product approved by the FDA, there are other microbiota-based agents in the pipeline.
Katrine Wallace, PhD, and Eric John Burnett, MD, discuss the distinctions between them and strategies to understand better the information people are consuming.
Key opinion leaders provide some advice for the public regarding COVID-19 booster shots and look to the future of the pandemic.
A rare case of Pott puffy tumor occurs in an atypical patient with no risk factors, likely due to untreated sinus infection.
Guest author Seth Lederman, MD, calls Long COVID "one of the most pressing global health threats I have seen since fighting HIV/AIDS."
Paul Radspinner, MBA, president and CEO of FluGen, addresses the safety profile, noting the low adverse event rates highlighting the safety and tolerability of the H3N2 M2SR influenza vaccine.
Deborah Birx, MD, and Amy Carenza, BBA, highlight the targeting of multidrug-resistant organisms and tracking of infection trends without increasing staffing needs.
Between those infected and uninfected with COVID-19, investigators observed no differences in symptom trajectories, assessed through SymptoMScreen.
The International Society for Infectious Diseases (ISID) ProMED surveillance system is a way for clinicians and interested ID stakeholders to be aware of local outbreaks and follow-up in response to get more information on them.
This bipartisan initiative highlights the need for a comprehensive approach to combat antimicrobial resistance (AMR), incorporating both antibiotic drug development and increased funding for stewardship programs.
From the discovery of penicillin to PK-PD principles: A brief historical overview and what we have learned from recent clinical trials.
Gonococcal septic polyarthritis is an uncommon manifestation of N gonorrhoeae infection, but has increased by about 40% in recent years.
Although this patient had none of these common risk factors associated with Candida empyema, she did have other factors predisposing her to fungal colonization and subsequent infection.
With an increased incidence of this sexually transmitted infection, a review of an older antibiotic for treatment has shown some clinical benefits in other countries.
Findings increasingly suggest the mortality risk may be reduced by initiating daptomycin within 3 days of infection.
Tina Tan, MD; Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP; Priya Nori, MD; Jacinda Abdul-Mutakabbir, PharmD; and Kevin Michael Reiter, MD, PA, provide key takeaways from the discussion on the treatment of respiratory viral infections.
Demystifying clinical data for treating invasive AmpC-harboring Enterobacterales.
A food for thought as an ambulatory antibiotic stewardship initiative.
This novel therapeutic option represents the first long-acting injectable approved for maintenance of HIV-1 suppression.
Scott Bertani, who is the director of Advocacy of the National Coalition for LGBTQ Health, discusses what the new mpox health declarations mean to the US, which groups are high risk, and information about the vaccine to prevent the disease.
Will there be an answer to keep the continuously evolving virus at bay? Are seasonal combination vaccines the wave of the future?
Current prevention strategies include two injectables for infants and young children, namely palivizumab and nirsevimab.
Hepatitis B virus vaccination shown to to significantly improve survival rates for patients with chronic hepatitis C, nonalcoholic liver disease, and liver cirrhosis.
At MAD-ID 2025, William R Mikesell, PharmD, presented data showing 20% vs 16% treatment failure rates in doxycycline and minocycline groups.
At MAD-ID 2025, Rachel M. Kenney, PharmD, discusses treatment shifts, microbiome innovations, and pharmacists' roles in optimizing outcomes.